3-(4-chlorophenyl)-4-methyl-1H-pyrazol-5-amine | 1093060-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-chlorophenyl)-4-methyl-1H-pyrazol-5-amine
• 英文别名: 5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-amine
• CAS: 1093060-49-1
• 化学式: C₁₀H₁₀ClN₃
• 分子量: 207.662
• InChiKey: CFRKMAJPPYXCPT-UHFFFAOYSA-N

物化性质

• 沸点：
  433.2±45.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4-[(E)-3-(dimethylamino)prop-2-enoyl]-5-methyl-N,1-diphenylpyrazole-3-carboxamide 、 3-(4-chlorophenyl)-4-methyl-1H-pyrazol-5-amine 以 吡啶 为溶剂， 反应 48.0h， 以70%的产率得到4-[2-(4-chlorophenyl)-3-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methyl-N,1-diphenylpyrazole-3-carboxamide
  参考文献：
  名称：

  Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity

  摘要：

  The versatile synthons 4-(2-bromoacetyl)-5-methyl-1-phenyl-3-phenylcarbamoyl-1H-pyrazole ( 3) and 4-[( E)-3-(dimethylamino) acryloyl]-5-methyl-1-phenyl-3-phenylcarbamoyl-1H-pyrazole ( 2) were used as precursors for the synthesis of a series of phenylpyrazoles with different aromatic ring systems at position 4. The antimicrobiological evaluation of the newly synthesized compounds was carried out in vitro assays for antifungal and antibacterial activities. Amongst the tested compounds, 4-acetyl-5methyl-1-phenyl-3-phenylcarbamoyl-1H-pyrazole (1), 4-[( E)-3-(dimethylamino) acryloyl]-5-methyl-1-phenyl-3-phenylcarbamoyl-1H- pyrazole (2),4-(2-bromoacetyl)-5-methyl-1-phenyl-3-phenylcarbamoyl-1H- pyrazole (3) and 4-(2-aminothiazol-4-yl)-5-methyl-1-phenyl-3-phenylcarbamoyl-1H- pyrazole ( 17) showed interesting antimicrobial properties. In particular, all tested compounds produced inhibitory effects against pathogenic yeast (Candida albicans) similar or superior to those of reference drug. In addition, compound 3 showed excellent activity against pathogenic mould ( Aspergillus). From structure-activity relationship (SAR) point of view, the attachment of bromoacetyl moiety to pyrazole ring can be considered as a breakthrough in developing a new therapeutic antifungal agent related to phenylpyrazole system. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.043
• 作为产物：
  描述：

  3-(4-chlorophenyl)-2-methyl-3-oxopropanenitrile 在 肼 作用下， 以 乙醇 为溶剂， 反应 1.75h， 以64.4%的产率得到3-(4-chlorophenyl)-4-methyl-1H-pyrazol-5-amine
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES
  [FR] COMPOSÉS ET PROCÉDÉS PERMETTANT DE TRAITER DES MALADIES DÉPENDANT DE MÉTALLOPROTÉASES À ZINC MATRICIELLES

  摘要：

  本发明提供了用于治疗锌基质金属蛋白酶依赖性疾病的化合物和方法。在某些实施例中，本发明的化合物具有以下公式：

  公开号：

  WO2009045761A1

文献信息

• METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT
  申请人：Jacobson Alan

  公开号：US20110190285A1

  公开（公告）日：2011-08-04

  The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas: (I), (II), (III), (IV), (V).

  本发明提供了治疗受体肉毒毒素相关疾病的方法。在某些实施例中，该方法涉及到给受体注射以下化合物：(I)、(II)、(III)、(IV)、(V)。
• COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES
  申请人：Jacobson Alan

  公开号：US20110034521A1

  公开（公告）日：2011-02-10

  The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas:

  本发明提供了化合物和治疗锌基金属蛋白酶依赖性疾病的方法。在某些实施例中，本发明的化合物具有以下结构式：
• Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives
  申请人：RICHTER GEDEON NYRT.

  公开号：US10960007B2

  公开（公告）日：2021-03-30

  The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.

  本发明涉及新的式（I）吡唑并[1,5-a]嘧啶衍生物或其药学上可接受的盐、生物活性代谢物、原药、外消旋体、对映体、非对映异构体、溶液和水合物，可作为 GABAB 受体正异位调节剂。本发明还涉及生产此类化合物的工艺。本发明进一步涉及包含此类化合物的药物组合物（可选择与两种或两种以上不同的治疗剂组合），以及此类化合物在治疗由 GABAB 受体正性异位调节机制介导和调节的疾病和病症的方法中的用途。本发明还提供了一种用于治疗此类疾病的药物的制造方法。
• Switchable selectivity in multicomponent heterocyclizations of acetoacetamides, aldehydes, and 3-amino-1,2,4-triazoles/5-aminopyrazoles
  作者：Elena A. Muravyova、Sergey M. Desenko、Roman V. Rudenko、Svetlana V. Shishkina、Oleg V. Shishkin、Yulia V. Sen’ko、Elena V. Vashchenko、Valentin A. Chebanov

  DOI：10.1016/j.tet.2011.09.138

  日期：2011.12

  Multicomponent heterocyclizations of 3-amino-1,2,4-triazoles/5-aminopyrazoles with acetoacetamides and aromatic aldehydes were studied in detail using conventional thermal heating, ultrasonication, and microwave irradiation. Several different synthetic pathways for these cyclocondensations occurring under either kinetic or thermodynamic control were established depending on the temperature regime and building block selection. The experimental data obtained and the procedures developed allow tuning selectivity of the multicomponent reactions studied. (C) 2011 Elsevier Ltd. All rights reserved.
• LACTAM INHIBITORS OF FXa AND METHOD
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP1156803A1

  公开（公告）日：2001-11-28